Further supporting the role of ceramide biosynthesis in diabetic kidney disease, large-scale genetic studies have linked a common deleterious missense variant in ceramide synthase-2 (CERS2), a ceramide-synthesizing gene in the sphingolipid biosynthesis pathway, with reduced renal function and diabetic kidney disease risk27,28. This evidence concerns the gene CERS2 and diabetic kidney disease.